HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - HIMS

Core Viewpoint - Hims & Hers Health, Inc. is facing securities class action lawsuits due to allegations of failing to disclose material information during the class period, which has resulted in significant financial losses for investors [3][4]. Group 1: Legal Actions - Investors have until August 25, 2025, to file lead plaintiff applications in the ongoing securities class action lawsuits against Hims & Hers Health, Inc. for purchases made between April 29, 2025, and June 23, 2025 [1][2]. - The lawsuits are pending in the United States District Court for the Northern District of California, with the first case filed being Sookdeo v. Hims & Hers Health, Inc. [5]. Group 2: Company Issues - Novo Nordisk terminated its partnership with Hims on June 23, 2025, citing violations of laws regarding the sale of compounded drugs and concerns over patient safety due to deceptive marketing practices [4]. - Following the announcement of the partnership termination, Hims' share price dropped by $22.24, or 34.6%, closing at $41.98 per share on June 23, 2025, amid unusually high trading volume [4]. Group 3: Law Firm Background - Kahn Swick & Foti, LLC, the law firm handling the lawsuits, is recognized as one of the top boutique securities litigation firms in the U.S., serving both institutional and retail investors [5].